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OBJECTIVE—Noninvasive determination of pancreatic -cell
mass in vivo has been hampered by the lack of suitable -cell–
speciﬁc imaging agents. This report outlines an approach for the
development of novel ligands homing selectively to islet cells in
vivo.
RESEARCH DESIGN AND METHODS—To generate agents
speciﬁcally binding to pancreatic islets, a phage library was
screened for single-chain antibodies (SCAs) on rat islets using
two different approaches. 1) The library was injected into rats in
vivo, and islets were isolated after a circulation time of 5 min. 2)
Pancreatic islets were directly isolated, and the library was
panned in the islets in vitro. Subsequently, the identiﬁed SCAs
were extensively characterized in vitro and in vivo.
RESULTS—We report the generation of SCAs that bind highly
selective to either -o r-cells. These SCAs are internalized by
target cells, disappear rapidly from the vasculature, and exert no
toxicity in vivo. Speciﬁc binding to -o r-cells was detected in
cell lines in vitro, in rats in vivo, and in human tissue in situ.
Electron microscopy demonstrated binding of SCAs to the endo-
plasmatic reticulum and the secretory granules. Finally, in a
biodistribution study the labeling intensity derived from [
125I]-
labeled SCAs after intravenous administration in rats strongly
predicted the -cell mass and was inversely related to the
glucose excursions during an intraperitoneal glucose tolerance
test.
CONCLUSIONS—Our data provide strong evidence that the
presented SCAs are highly speciﬁc for pancreatic -cells and
enable imaging and quantiﬁcation in vivo. Diabetes 58:2324–
2334, 2009
T
he ability to noninvasively measure pancreatic
-cell mass in vivo may provide an early diag-
nostic tool for the diagnosis of type 1 diabetes
and potentially promote the development and
evaluation of novel therapeutic strategies. However, de-
spite enormous efforts by various groups, none of the
approaches tested have permitted a reliable and noninva-
sive assessment of -cell mass in humans.
The small size of islets (50–300 m in diameter), their
low abundance (1–2% of pancreatic mass), and their
scattered distribution throughout the pancreas create
technical challenges for noninvasive imaging of -cell
mass. Because pancreatic islets possess no intrinsic con-
trast from the surrounding exocrine tissue, imaging tech-
niques have focused on detecting the pancreatic islet with
exogenous agents that are preferentially bound or concen-
trated in islets, and an extensive library of radiolabeled
agents has been applied to islet imaging. However, radio-
labeled compounds targeting the sulfonylurea receptor
(1–5), the presynaptic vesicular acetylcholine transporter
(6), and dopamine uptake in synaptic vesicles (7) have not
proven to be effective for islet imaging, most likely be-
cause of their failure to achieve the required endocrine-to-
exocrine binding ratio (100:1), as suggested by Sweet et
al. (8,9). Another proposed strategy to image islets within
the pancreas relates to radiolabeled peptides derived from
glucagon-like peptide 1 (GLP-1) or its analogues, taking
advantage of the observation that the GLP-1 receptor is
expressed at a high density in the islets, but not in
exocrine cells (10). This approach has proven useful for
imaging insulinomas (11), but has not yet been demon-
strated to allow for the determination of islet cell mass in
healthy humans or patients with diabetes. Harris and
colleagues used [
11C]DTBZ, a ligand to vesicular mono-
amine transporter 2 (VMAT2), to image pancreatic islets in
rodents and humans (12–14) by the means of positron
emission tomography (PET). Although initial results with
DTBZ have been rather encouraging (12,13), recent ﬁnd-
ings suggest that nonspeciﬁc, non–-cell binding of
[
11C]DTBZ in the pancreas may limit its utility as a -cell
imaging agent in humans (14).
An obvious reason for these difﬁculties in generating a
valuable imaging agent is the paucity of knowledge about
potential targets that are exclusively expressed on the
-cell surface. One way to overcome these limitations is to
use phage-display technology, a powerful approach for
isolating target-speciﬁc peptides and antibodies in animals
and humans (15,16). Such single-chain antibodies (SCAs)
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been isolated by recovering infectious phages from within
cells after receptor-mediated endocytosis (17). For exam-
ple, internalizing SCAs targeting erbB2 and epidermal
growth factor receptor have been identiﬁed and used to
speciﬁcally deliver drugs into breast cancer cells (18,19).
Therefore, in the present study, we applied repeated phage
panning and rescued the bound phages from within the
islet cells to isolate SCAs speciﬁcally internalizing in islet
-cells. These SCAs were then further characterized and
evaluated with respect to their suitability for islet imaging
purposes.
RESEARCH DESIGN AND METHODS
Animal model and human tissue samples. Female CD-rats (6 weeks of age;
200–250 g) received a single intraperitoneal injection of streptozotocin (STZ)
14 days before experiment. To induce different amounts of -cell mass
reduction, rats were treated with either 30 mg/kg (low dose; n  5) or 60
mg/kg (high dose; n  5) STZ. All animal studies were approved by the
Landesamt fu ¨r Naturschutz (Recklinghausen, Germany, no. 50.10.32.08.037).
The use of nondiabetic human pancreatic tissue samples was approved by the
ethics committee of the Ruhr-University Bochum (no. 2528, amendment 3).
Phage library. The recombinant phage library Tomlinson I is constructed in
the pIT2 vector (derived from pHEN1), consists of about 1.4  10
8 different
human single-chain variable fragments, and was provided by MRC Geneser-
vice (Cambridge, U.K.). The library is based on a single human framework for
VH (V3–23/DP-47 and JH4b) and V (O12/O2/DPK9 and J 1) with diversiﬁed
(DVT) side chains incorporated in complementarity-determining region (CDR)
2 and CDR 3.
Phage library screening. The library was screened for islet-speciﬁc SCAs
using two approaches. 1) For in vivo screening, a nondiabetic CD-rat was
injected intravenously through the jugular vein with 10
12 phage transducing
units and allowed to circulate for 5 min. The pancreas was removed, and to
recover islet bound phages, the islets were isolated according to a standard
protocol except the use of FCS (20). 2) For in vitro screening, directly isolated
rat islets were incubated with 10
12 phage transducing units for 1 h at 37°C in
vitro, as described previously (21). Subsequently, islets from both approaches
were treated equally to rescue phages from within the islet cells. Brieﬂy, the
islets were washed twice by suspension in 1 ml PBS, followed by lysing the
cells by the addition of 1-ml hypotonic solution (30 mmol/l Tris-HCl, pH 8.0)
and a single freeze–thaw cycle. Subsequently, the suspension was incubated
overnight with TG1 bacteria at 37°C, with transducing units determined to
monitor the progress of each round of library panning and the phages
ampliﬁed according to standard protocols for use in the next round (22).
Puriﬁcation of SCAs. HB2151 bacteria (OD600  0.4) were infected with 10
l of isolated phage clones of interest, and colonies were further grown in 2 
TY (100 g/ml ampicillin and 1% glucose). Isopropyl -D-thiogalactoside
(IPTG; AppliChem, Darmstadt, Germany) was added to induce SCA expres-
sion. The supernatant containing the SCAs was puriﬁed by metal afﬁnity
chromatography (Nunc ProPur, Nunc, Langenselbold, Germany). The purity
of the sample was checked by SDS gel electrophoresis and Western blotting.
Immunohistochemistry. Staining of formalin-ﬁxed, parafﬁn-embedded rat
and human tissue sections (5 m) was performed as follows: Sections were
deparafﬁnized using xylol twice for 10 min and followed by EtOH thrice for 5
min and Aqua dest. for another 5 min. Afterward, the sections were perme-
abilized by heating in the microwave in antigen unmasking solution pH 6 and
down cooling for 45 min. Blocking was done for1ha t24°C with PBS
containing 2% BSA. Primary and secondary antibodies were diluted in PBS
with 2% BSA. Primary antibodies were incubated at 4°C overnight, except for
insulin and glucagon with an incubation period of1ha t37°C. Secondary
antibodies were incubated for 30 min at 24°C, and the same holds true for the
Cy2- and Cy3-conjugated streptavidin reagents. The following primary anti-
bodies and dilutions were used: SCA B1 and SCA A1, 1:200; monoclonal mouse
anti-c Myc antibody, 1:200 (Cell Signaling, 2276); polyclonal guinea pig anti-
swine insulin antibody, 1:400 (Dako, A0564); and monoclonal mouse
antiglucagon antibody, 1:200 (Afﬁnity BioReagents, MA1-20210). Secondary
antibodies were monoclonal mouse anti-c Myc antibody, 1:200 (Cell Signal-
ing, 2276); biotinylated anti-rabbit IgG and biotinylated anti-mouse IgG, 1:200
A A M A E V Q L L E S G G G L V Q P G G S L R L S C A A S X X X X X X X X X X W V R Q A P G 
CDR-H1
K G L E W V S X X X X X X X X X X X X X X X X X X X T I S R D N S K N T L Y L Q M N S L R 
CDR-H2
A E D T A V Y Y C A X X X X X X D Y W G Q G T L V T V S S G G G G S G G G G S G G G G S T  
CDR-H3 Linker 
P S D I Q M T Q S S L S A S V G D R V T I T C X X X X X X X X X X X W Y Q Q K P G K A P K L 
CDR-L1
L I Y X X X X X X X G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C X X X X X
CDR-L2 CDR-L3
X X X X F G Q G T K V E I K R A A A H H H H H H G A A E Q K L I S E E D L N 
His-Tag 
B
CDR-H1:
ISPC 1  G F T F S S Y A M S
ISPC 2  G F T F S S Y A M S
ISPC 3  G F T F S S Y A M S
ISPC 4  G F T F S S Y A M S
ISPC 5  G F T F S S Y A M S
ISPC 6  G F T F S S Y A M S
CDR-H2:
ISPC 1  S I T A E G T H T W Y A D S V K G R F
ISPC 2  R I K I F  G S K T K  F A D S  V K G R F  
ISPC 3  R I S V A G R R T A Y A D S V K G R F
ISPC 4  P I A S R G A R T N Y A D S V K G R F  
ISPC 5  S I H P K G Y P T R Y A D S V K G R F  
ISPC 6  R I Q F F G S H T Y F A D S V K G R F  
CDR-H3:
ISPC 1  K T S YR F
ISPC 2  K H S TH F
ISPC 3  K K RPP F
ISPC 4  K K P SS F
ISPC 5  K S T TP F
ISPC 6  K H STH F 
C
CDR-L1:
ISPC 1  R A S Q S I S S Y L N
ISPC 2  R A S Q S I S S Y L N
ISPC 3  R A S Q S I S S Y L N
ISPC 4  R A S Q S I S S Y L N
ISPC 5  R A S Q S I S S Y L N
ISPC 6  R A S Q S I S S Y L N
CDR-L2:
ISPC 1  K A S R L Q S  
ISPC 2  R A S S L Q S
ISPC 3  A A S S L Q S 
ISPC 4  K A S P L Q S
ISPC 5  A A S S L Q S
ISPC 6  R A S I L Q S
CDR-L3:
ISPC 1  Q Q K W D P P R T  
ISPC 2  Q Q L Q S T P R   T
ISPC 3  Q Q M G R D P R T
ISPC 4  Q Q S M Q V P S  T
ISPC 5  Q Q M G R D P R T
ISPC 6  Q Q N  R R I P R  T  
FIG. 1. Shown are the amino acid sequences of the - and -cell–speciﬁc ISPCs. A: Amino acid sequences of heavy (H, red) and light (L, blue)
chain. Boxes indicate the CDRs. X  variable amino acids within CDRs. B and C: Comparison of amino acids within CDR-H1-CDR-H3 (B) and
within CDR-L1-CDR-L3 (C) (variable amino acids are marked in green).
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diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2325(Linaris, BA-1000, BA-2001); Cy3-conjugated goat anti-mouse IgG, 1:200 (Jack-
son ImmunoResearch Laboratories, 115-165-044); Cy3-conjugated goat anti-
guinea pig IgG, 1:800 (Jackson ImmunoResearch Laboratories, 106-165-003).
Third reagents were Cy2-conjugated streptavidin, 1:200 (Jackson ImmunoRe-
search Laboratories, 016-220-084). Tissue slides were analyzed using a Zeiss
Axioplan microscope.
Electron microscopy. Rats were transcardially perfused with PBS (2.5%
glutaraldehyde) before pancreas extraction, postﬁxed in 2.5% (wt/vol) glutar-
aldehyde, rinsed with PBS, postﬁxed in 1% osmiumtetroxide, dehydrated in
ascending concentrations of ethanol and propylenoxide, and embedded in
durcupan. Ultrathin sections were incubated with the anti-c Myc antibody
(1:100; Cell Signaling, 2276) and a biotinylated anti-mouse IgG, 1:200 (Linaris,
BA-2001). Finally, all sections were stained with gold-labeled streptavidin
particles (1/20, 10 nm; Aurion, Wageningen, the Netherlands). After rinses,
sections were postﬁxed with 2.0% (wt/vol) glutaraldehyde for 5 min and
counterstained. Sections were analyzed on a Zeiss 109 transmission electron
microscope.
Labeling SCAs with
125I. The SCAs (0.1 mg) were labeled with
125I using the
chloramine-T method as described previously (23).
Cell culture. INS-1 (kind gift from C. Wollheim, Geneva), AR42J (ATCC,
Manassas, VA), and -TC1 cells (ATCC, Manassas, VA) were grown (23,24)
and processed as described (23).
Radioactive in vitro assay. The assay was performed as described previ-
ously (23), except that an electronic pulse area analysis (CASY Technology,
Reutlingen, Germany) was used to estimate the average cell volume (ﬂ). To
evaluate speciﬁcity of binding, SCAs were preincubated with selected unla-
beled SCAs (20 g) for competition assays.
Pharmacokinetic analysis. Rats injected with 100 g radiolabeled SCAs
were killed at indicated time points, and blood samples were obtained,
followed by sedimentation of cellular material and precipitation of superna-
tant with trichloroacetic acid. Radioactivity associated with pellets and
supernatant was measured. Blood content of radiolabel was expressed as a
percentage of injected dose per gram of blood (%ID/g).
Intraperitoneal glucose tolerance test. CD-rats received an intraperito-
neal glucose tolerance test (IPGTT) 7 days after intravenous injection of SCAs.
Rats were fasted for 4 h before the experiments. After baseline blood
sampling, animals received an intraperitoneal injection of glucose (2 g/kg
body wt) with glucose, insulin, and glucagon levels measured at 30, 60, and
120 min later. Blood samples were taken from tail vein, and glucose was
determined by a clinical analyzer (Nova Biomedical, Ro ¨dermark, Germany),
insulin with ELISA (Mercodia, Uppsala, Sweden), and glucagon with an
enzyme immunosorbent assay (Alpco, Salem, NH).
Cell viability and apoptosis. INS-1 or -TC1 cells (10
6) were exposed
overnight to SCAs (5 go r2 0g). Apoptosis was assessed with FITC-
Annexin-V/propidium iodide (Pharmigen), and analysis was performed with a
FACSscan ﬂow cytometer. Viability was determined by staining the cells with
calcein-AM (Calbiochem) and propidium iodine (Molecular Probes), photo-
graphed with a ﬂuorescence microscope connected to a digital camera, and
images were digitally processed using Cell P software (Olympus) and Photo-
shop 6.0 software (Adobe) (25). Values were compared with those in
nontreated controls.
Biodistribution of [
125I]-SCA B1, IPGTTs, and estimation of -cell
mass. In this set of experiments, an IPGTT was performed 14 days after
diabetes induction (see above for details of these procedures, except that
insulin and glucagon levels were not determined) in low-dose STZ (n  5;
fasting plasma glucose [FPG]: 250  10 mg/dl), high-dose STZ (n  5; FPG:
490  97 mg/dl), and nondiabetic control rats (n  7; FPG: 90  14 mg/dl). On
the following day, the [
125I]-SCA B1 (each animal got 0.002 Ci/g of body wt)
was injected intravenously in these animals. Two hours after injection, the
animals were killed, and pancreases were removed, weighed, and assayed in
a gamma counter for radioactivity (26). Accumulation of SCA B1 was
expressed as a %ID/g of tissue, corrected for background, and estimated in the
glandula parotis. The -cell mass of the corresponding pancreases was
estimated by morphometry (27) according to the following formula: -cell
fraction (%)  insulin-positive area/total pancreatic area; -cell mass per
pancreas (milligram)  -cell fraction  pancreatic weight (milligram).
Statistics. Curve ﬁts were modeled in form of nonlinear regression. For
washout experiments, data were adapted to an exponential decay function
with y  a  b*exp(	c*x), where x denotes the time axis and y the measured
count rate. For saturation experiments, results were adapted to an exponen-
tial rise function as y  a  b*(1 	 exp[	c*x]). Decision criteria were squared
regression coefﬁcients (r
2). Parametric comparisons of continuous data were
calculated with Student’s t test for unpaired data with unequal variance. Main
null hypothesis was equal distribution of measured counts in both investigated
cell types or with and without preincubation, respectively. Area under the
curve (AUC) for glucose, insulin, and glucagon was calculated using the
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FIG. 2. Immunoﬂuorescence analyses of binding selectivity to pan-
creatic islets after intravenous application of ISPCs, a control ISPC
without an insert, or SCAs in a rat (n  4 rats per group, 30–40
sections and 60–80 islets per rat). Double staining of ISPCs (A–F,
green) and insulin (A, C, and E, red) or glucagon (B, D, and F, red)
and nucleus using DAPI (blue). The ISPC1 (A and B) colocalized
exclusively with insulin, whereas the ISPC3 (C and D) colocalized
selectively with glucagon. In contrast, the control ISPC without an
insert (E and F) was not detectable in the islets. In another set of
experiments, double staining of SCAs (G–J, green) and insulin (G
and I, red) or glucagon (H and J, red) and nucleus using DAPI (blue)
was performed. This conﬁrmed the highly selective uptake of SCA
B1 in -cells (G and H) and of SCA A1 in -cells (I and J). All images
were acquired at magniﬁcation 40. (A high-quality digital repre-
sentation of this ﬁgure is available in the online issue.)
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4.0.3 for Macintosh Computers (Synergy Software, Reading, PA).
RESULTS
Generation of SCAs binding selectively to either -
or -cells in rats. To generate agents speciﬁcally binding
to pancreatic islets, a phage library was screened for SCAs
on rat islets using two different approaches: A: The library
was injected into rats in vivo, and islets were isolated after
a circulation time of 5 min. B: Pancreatic islets were
directly isolated, and the library was panned in the islets in
vitro. After ﬁve rounds of selection, a marked increase in
the phage transducing units per islet over successive
rounds of panning was found, demonstrating a 700- and
500-fold enrichment with approach A and B, respectively.
Subsequently, the DNA encoding the corresponding
phage-displayed SCAs was sequenced. By these means,
four islet-speciﬁc phage clones (termed ISPC1  SCA B1,
ISPC2  SCA B2, ISPC3  SCA A1, ISPC4  SCA A2) were
identiﬁed by approach A (Fig. 1). Approach B also yielded
four ISPCs, two of which were identical to those derived
from approach A (ISPC1 and 2). The other two ISPCs were
termed ISPC5 and 6 (SCA B3 and SCA B4).
Binding selectivity and subcellular localization of
SCAs. To determine the binding selectivity of the ISPCs
to rat islets in vivo, the ISPCs were injected intrave-
nously and allowed to circulate for 2 h. Subsequently,
the animals were killed and the pancreas and control
organs were harvested and prepared for immunohisto-
chemical analyses. Immunostaining for ISPC1 was
readily detectable in the cytoplasm of islet cells, where
it was colocalized to insulin, but not glucagon staining,
liver kidney spleen muscle                      lung
ISPC1
ISPC3
control
SCA B1
SCA A1
FIG. 3. Immunoﬂuorescence analyses of binding to control tissue after intravenous application of ISPCs, a control ISPC without an insert, or
SCAs in a rat (n  4 rats per group, 30–40 sections per rat). Staining in green color for ISPCs or SCAs. Nuclei were stained with DAPI in blue
color. Neither the IPSCs nor SCAs revealed any binding activity to the tested control organs. All images were acquired at magniﬁcation 40. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
FIG. 4. Ultrastructural analyses of exact intracellular localization of the
SCAs after intravenous application in a rat. Transmission electron micros-
copy detected the -cell–speciﬁc SCA B1 (A and B) and the -cell–speciﬁc
SCA A1 (C and D) in the endoplasmatic reticulum (A and C) and at the
secretory granule membrane (B and D) of the respective target cells exclu-
sively (n  4 rats per group, 20–30 sections per rat). Scale bars, 90 nm.
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Similar staining patterns were found for ISPC2, 5, and 6
(data not shown). In contrast, ISPC3 (Fig. 2C and D) and
4 (data not show) were found to be exclusively colocal-
ized with glucagon staining, indicating that these ISPCs
were selectively binding to islet -cells. Of note, no
binding to exocrine cells (Fig. 2A–D) and several other
control organs (liver, kidney, spleen, heart, and lung)
was detectable in any of the ISPCs (Fig. 3). Further-
more, control experiments using an ISPC without the
insert did not reveal any binding activity to pancreatic
islets or other structures (Fig. 2E and F).
Subsequently, soluble SCAs containing a c-Myc tag and
a His6 tag were generated from all six ISPCs in small-scale
cultures. These SCAs were then puriﬁed by metal afﬁnity
chromatography and administered intravenously into rats.
These experiments conﬁrmed the highly selective cyto-
plasmatic uptake of SCA B1 (Fig. 2G and H) and B2–4
(data not shown) in -cells and of SCA A1 (Fig. 2I and J)
and A2 (data not shown) in islet -cells, whereas no
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FIG. 5. Analyses of the binding process of selected [
125I]-labeled SCAs to different endocrine and exocrine cell lines in vitro and determination
of their pharmacokinetic proﬁles in vivo. Binding speciﬁcity of SCA B1 to INS-1 cells (A,* P  0.0016 vs. -TC1 or AR42J) and SCA A1 to -TC1
cells (B,* P < 0.0001 vs. INS-1 or AR42J). Time course of binding of SCA B1 to INS-1 cells (C,t 1/2  8.0 min) or SCA A1 to -TC1 cells (D,t 1/2 
5.3 min). Competition assay of SCA B1 (E,* P < 0.0001 vs. preincubation (PI) with SCA B1) or SCA A1 (F,* P < 0.0001 vs. preincubation with
SCA A1) with unlabeled SCAs. Dose response of SCA B1 binding to INS-1 cells (G, r
2  0.96) or SCA A1 to -TC1 cells (H, r
2  0.96). Time course
of elimination of SCA B1 (I,t 1/2  22.7 min, r
2  0.87) or SCA A1 (J,t 1/2  19.2 min, r
2  0.97) from the vascular system. Error bars represent SEM.
CAR, cell-associated radioactivity.
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tissues (liver, kidney, spleen, heart, and lung) was de-
tected for any of the SCAs (Fig. 3).
Finally, the SCAs were applied for electron microscopy
in rat pancreatic tissue. These analyses conﬁrmed the
selective cytoplasmatic localization of SCA B1 and SCA A1
for islet -cells (Fig. 4A and B) and -cells (Fig. 4C and D),
respectively. More speciﬁcally, selective binding to the
endoplasmatic reticulum and the secretory granules of the
respective target cells was found.
Binding properties of radiolabeled SCAs in vitro and
pharmacokinetic proﬁles in vivo. To determine the
respective binding properties of selected [
125I]-labeled
SCAs and to compare these characteristics with other
agents examined previously, a systematic in vitro analysis
was performed in the -cell line INS-1, the -cell line
-TC1, and the exocrine cell line AR42J. Binding of the
-cell–speciﬁc SCA B1 to INS-1 cells was 514 times higher
than binding to -TC1 and AR42J cells (Fig. 5A). In
contrast, the -cell–speciﬁc SCA A1 showed a 210-fold
higher binding speciﬁcity to -TC1 relative to INS-1 and
AR42J cells (Fig. 5B), consistent with the in vivo ﬁndings.
Furthermore, rapid binding characteristics were found for
both SCAs, with a binding half-life of 8.0 min for SCA B1 in
INS-1 cells (Fig. 5C) and a binding half-life of 5.3 min for
SCA A1 in -TC1 cells (Fig. 5D).
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of radiolabeled SCA B1 by preincubation with unlabeled
SCA A1 and vice versa (Fig. 5E and F), suggesting that the
binding and internalization of these SCAs were mediated
by different molecules. For both SCAs, binding saturation
could be demonstrated after preincubation with the cor-
responding unlabeled SCAs (Fig. 5E and F). The respective
dose-response curves revealed a maximum capacity of
650.307 SCA B1 molecules to be internalized per -cell and
of 669.945 SCA A1 molecules to be taken up per -cell (Fig.
5G and H).
Because any unbound label circulating in the vascula-
ture might theoretically interfere with the respective im-
aging signal of the bound label, the plasma clearance
kinetics of selected SCAs were determined in rats in vivo
(Fig. 5I and J). For these purposes, preparations of
radiolabeled SCAs were administered intravenously into
rats, and the respective radioactivity was measured in the
plasma over time. These experiments revealed a very rapid
elimination of both SCA B1 and SCA A1 from the circula-
tion (t1/2  22.7 min and 19.2 min, respectively).
Speciﬁc binding to human islets in situ. To use these
SCAs for the determination of islet cell mass in humans,
speciﬁc binding to human pancreatic -o r-cells would
be required. Therefore, human pancreatic tissue was
costained by immunohistochemistry using the SCAs as
well as speciﬁc antibodies for insulin and glucagon, re-
spectively. Staining for the -cell–speciﬁc SCA B1 was
clearly detectable within the islets and colocalized with
insulin expression, whereas no binding to -cells or exo-
crine cells was detectable (Fig. 6A and B). Conversely, the
-cell–speciﬁc SCA A1 overlapped with glucagon staining,
but neither with insulin staining nor with exocrine cells
(Fig. 6C and D).
In vivo toxicity tests. Because any interference of the
SCAs with islet cell function would clearly limit their
clinical applicability, IPGTTs were carried out 7 days after
the intravenous administration of the SCAs into rats. The
time course of plasma glucose, insulin, and glucagon levels
during the IPGTT was unchanged by the SCAs compared
with vehicle-treated animals (Fig. 7A–C), suggesting no
impairment in islet function. Furthermore, to rule out
direct toxic effects on islet cell turnover, cell viability (Fig.
7D) and apoptosis (Fig. 7E) were assessed in INS-1 or
-TC1 cells after overnight exposure to increasing
amounts of the SCAs in vitro. No inﬂuence of islet cell
turnover was found in these experiments.
Quantiﬁcation of -cell mass using [
125I]-SCA B1 in
rats. To test the ability of SCA B1 for the quantiﬁcation of
-cell mass in vivo, 14 days after diabetes induction by STZ
treatment, the [
125I]-SCA B1 was administered intrave-
nously into rats and allowed to circulate for 2 h. Subse-
quently, the animals were killed, and the accumulation of
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FIG. 5. Continued.
FIG. 6. Immunoﬂuorescent staining for binding of the SCAs to human
islets in a pancreas of a nondiabetic subject. SCAs, green; insulin or
glucagon, red; DAPI (nucleus), blue. The SCA B1 colocalized selec-
tively with insulin (A), but not glucagon staining (B). The SCA A1
colocalized with glucagon (C), but not insulin-expressing cells (D). All
images were acquired at magniﬁcation 40. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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125I]-SCA B1 was determined in the harvested pan-
creas. The measured radiolabeling intensity in the pan-
creas was then compared with the respective -cell mass
(determined by quantitative morphometry) and the glu-
cose excursions (AUC glucose) during an IPGTT (per-
formed the day before [
125I]-SCA B1 application).
Both -cell mass and the respective radiolabeling inten-
sity were higher in nondiabetic rats than in low- and
high-dose STZ-injected diabetic rats (Fig. 8A). A strong
positive correlation between the radiolabeling intensity of
the pancreas and -cell mass was found within all three
subgroups (r
2  0.937), with the respective probe accu-
mulation diminishing gradually with declining -cell mass.
Furthermore, an inverse relationship between radiolabel-
ing intensity and glucose excursions during the IPGTT was
observed (r
2  0.876, Fig. 8B).
Time (minutes)
0 30 60 120
p
l
a
s
m
a
 
g
l
u
c
o
s
e
 
(
m
g
/
d
l
)
0
50
100
150
200
250
300
350
0 30 60 120
i
n
s
u
l
i
n
 
(
µ
g
/
l
)
0
1
2
3
03 0 6 0 1 2 0
g
l
u
c
a
g
o
n
 
(
p
g
/
m
l
)
0
100
200
300
SCA B1
(20 µg) 
SCA A1
(5 µg) 
SCA A1
(20 µg) 
%
 
v
i
a
b
i
l
i
t
y
0
20
40
60
80
100
120
viable INS-1
non-viable IΝS-1
viable α-TC1
non-viable α-TC1
control SCA B1
(5 µg) 
SCA B1
(20 µg) 
SCA A1
(5 µg) 
SCA A1
(20 µg) 
control SCA B1
(5 µg) 
M
e
a
n
 
F
l
u
o
r
e
s
c
e
n
c
e
 
I
n
d
e
x
0
1000
2000
3000
4000
5000
6000
INS-1
α-TC1
A
B
C
D
E
Time (minutes)
Time (minutes)
FIG. 7. Effect of SCAs on islet function in vivo and cell viability in
vitro. Time course of (A) plasma glucose, (B) insulin, and (C)
glucagon levels in rats during an IPGTT, 7 days after intravenous
injection of -cell–speciﬁc SCA B1 (E, n  5), -cell–speciﬁc SCA A1
( , n  5) or in vehicle-treated rats (F, n  5). D and E: Viability of
INS-1 and -TC1 cells (D) and (E) ﬂow cytometric analysis of cells
stained for the apoptosis marker FITC-Annexin-V after overnight
exposure to SCAs in vitro compared with nontreated controls (n  6
experiments). Error bars represent SEM.
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We report the successful isolation of six SCAs highly
speciﬁc for either -o r-cells both in rodents and in
humans. Furthermore, a direct correlation between pan-
creatic uptake of radiolabeled SCAs and -cell mass was
observed in normal and diabetic animals.
Antibodies have been used for cell-speciﬁc delivery of
therapeutic compounds, e.g., tumor-speciﬁc delivery of
chemotherapeutics (28). Therefore, it is reasonable to
suppose that antibodies directed against a highly speciﬁc
-cell molecule would be of clinical utility for imaging the
-cell mass. In this context, Moore et al. (26) used a
[
111In]-labeled IC2 antibody, directed against an unknown
molecule, which showed excellent correlation between
probe accumulation and -cell mass ex vivo. However,
because of the IgM nature of the antibody, a very slow
excretion from the vasculature (several days) was evident,
leading to an unfavorable signal-to-background ratio in
vivo (29). In another study, Ladriere et al. (30) evaluated a
[
125I]-labeled mouse monoclonal antibody (R2D6) directed
against a -cell surface ganglioside. Although the binding
of [
125I]-R2D6 was higher in isolated islets than in acinar
tissue, no signiﬁcant difference was detected when com-
paring islets from normal and rats rendered diabetic by
STZ. Recently, Hampe et al. (23) tested another -cell–
speciﬁc IgM antibody (K14D10) and concluded that the
speciﬁcity was far below that required to overcome the
signal-to-background ratio in vivo. However, it has been
reported that removal of the Fc portion to produce an
antibody fragment or an SCA reduces blood clearance
time and nonspeciﬁc binding (31,32). Therefore, antibody-
mediated targeting of -cells seems to be a promising
approach; however, an antibody with excellent binding
characteristics, but with a much faster clearance from the
vasculature, would need to be developed.
Here, we report the application of a phage-panning
approach in rodents to generate SCAs with highly speciﬁc
binding to pancreatic -cells in vivo. By these means, we
succeeded to isolate four SCAs that are selectively inter-
nalized into rodent -cells in vivo, home to the endoplas-
matic reticulum and the insulin secretory granules, and
bind to human -cells in situ. Furthermore, two additional
SCAs homing to islet -cells were identiﬁed. These SCAs
were highly speciﬁc for their respective target cells with
no relevant binding to other islet cells, exocrine cells, or
other tissues and with a calculated in vitro selectivity of
500:1 for -cells and 200:1 for islet -cells. These
numbers are far in excess of these reported previously for
other potential -cell mass imaging compounds and meet
the requisite exocrine-to-endocrine binding ratio needed
to distinguish -cells (8,9).
Although these studies cannot completely clarify the
precise mechanisms subserving the rapid and high-volume
(650,000 SCAs/cell) binding and cellular uptake of SCAs
to either -o r-cells, a membrane receptor-mediated
endocytosis appears to be most likely. Moreover, we
propose that the intracellular localization of the antibodies
has resulted from our screening strategy, which involved
lysis and homogenization, meaning that the membrane-
bound antibodies were likely eliminated, whereas the
intracellular ones were rescued, ampliﬁed, and reinjected
several times. Such mechanism would be consistent with
previous studies in this area in other cell types (17–
19,33,34) and would also be consistent with the competi-
tive binding characteristics of different SCAs at - and
-cells. However, although it seems highly likely that the
intracellular uptake of the SCAs was indeed receptor
mediated, the speciﬁc molecular target remains to be
elucidated.
Another important characteristic of the presently de-
scribed SCAs in favor of a diagnostic application in vivo is
the avid elimination of the unbound particles from the
circulation. These properties are in line with recent stud-
ies showing a rapid elimination of SCAs mainly via the
kidneys and have been attributed to their rather low
molecular weight (
31 kDa) (32,35).
In addition, this proof of concept study found no alter-
ation of islet turnover or islet function by the respective
SCAs. However, more detailed experiments will be re-
quired (dose-escalating studies in vivo, repeated applica-
tions in vivo, etc.) to completely rule out any toxicity or
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FIG. 8. Correlation of -cell mass and AUC for glucose during an IPGTT with pancreatic uptake of [
125I]-SCA B1 after its intravenous application
in a rat. Experiments were performed 14 days after diabetes induction. Linear regression analyses show a close correlation between pancreatic
uptake of SCA B1 and -cell mass in normal ( ), low- (E), and high-dose (F) STZ animals (A, r
2  0.937). Moreover, a strong nonlinear
association between the probe accumulation in the pancreas and the AUC for glucose during an IPGTT in the respective animals was depicted (B,
r
2  0.876). Each data point represents an animal.
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SCAs can be safely applied to humans.
Finally, the SCA B1 tested herein has proven to not only
label islet -cells in vitro or in human pancreas in situ but
also provide an excellent tracer for the radiolabeling of
-cells in vivo. Thus, the labeling intensity derived from
the [
125I]-SCA B1 after intravenous administration in rats
in vivo strongly predicted the respective -cell mass and
was inversely related to the glucose excursions during an
IPGTT, even though insulin secretion was not directly
assessed in this study. Therefore, our data provide strong
evidence that the SCAs characterized herein allow for the
imaging and quantiﬁcation of -cell mass in vivo, which
has to be conﬁrmed in future studies using noninvasive
imaging techniques such as PET.
In conclusion, we have generated SCAs that bind spe-
ciﬁcally to -o r-cells of rodent or human origin and
exhibit a high selectivity for their respective target cells
over other tissues. These radiolabeled SCAs have proven
to reliably predict -cell mass in rodent models of diabetes
after in vivo administration. We propose that such SCAs
combined with less invasive imaging techniques, such as
PET, may be suitable for the in vivo determination of -cell
mass in humans.
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